EN DE
Watch DT&CRO Co. Ltd. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

DT&CRO Co. Ltd. (383930) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of DT&CRO Co. Ltd. stock ₩1,970, price ₩1,890, upside +4.2%, quality 33 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

DC DT&CRO Co. Ltd. logo Thin data Nov 16, 2026

DT&CRO Co. Ltd.

383930 · KQ

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Fair value ₩1,970 · Fairly valued 
Expensive Growth (revenue 3y +2.8 %/yr in KRW) 
Moderate debt 
Mixed vs. peers (5/10) 
Quality 33/100 
Falling price (downtrend) 
Loss-making · -34.9% net margin (TTM) 
Negative free cash flow 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch DT&CRO Co. Ltd. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₩24,400 ₩1,450 Fair Value ₩1,970 Nov 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

48‑month range ₩1,450 – ₩24,400 · fair‑value band ₩1,478 – ₩2,463 · the ₩1,890 price screens below the ₩1,970 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow DT&CRO Co. in your weekly email

Every Wednesday you see whether DT&CRO Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea.

Show moreShow less

The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional food, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting.

DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin-si, South Korea.

Stock analysis

DT&CRO Co. Ltd. (383930) currently trades at ₩1,890, while our estimate is ₩1,970, so the stock looks roughly fairly valued today (gap 4.0%).

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ₩1,478 (bear) to ₩2,463 (bull), the price of ₩1,890 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

DT&CRO Co. Ltd. reported revenue of 47.7B KRW in FY2025 versus 32.7B KRW in FY2021, a compound +9.9%/yr. Reported net income was −2.8B KRW in FY2025.

Key figures

Market cap 24.2B KRW (≈ $18.1M) Micro · P/S ratio 0.51 · EPS (TTM) ₩-1,337 · Net margin −34.9% · Return on equity −105% · Return on assets (EBIT) −3.8% (5-year average) · Operating margin −58.1% · Revenue (TTM) 49.0B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 50% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at 4%, 383930 screens cheaper than that median.

Fair Value

Bear ₩1,478 Fair Value ₩1,970 Bull ₩2,463
Price ₩1,890 · Upside +4.2%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 16
Debt, balance sheet and risk of trouble
Investment 47
Does it invest with discipline instead of growing at any price?
Low Volatility 26
How calm the share price moves, does not count
Price momentum 31
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 79
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 12/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+32.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.0% (2021) → −12.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 383930, get fair value alerts →

Compare DT&CRO Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 856 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 33 · Below median
Fair Value upside +4.2% · Top 25%
Profitability
Return on assets −3.1% · Above median
Net margin (12 months) −34.9% · Below median
Operating margin (12 months) −58.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 12.3% · Above median
Balance sheet
Debt / equity 0.51× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.96× · Cheapest 25%
P/S (12 months) 0.49× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)39 · sector 5
FUTURE (revenue growth)62 · sector 31
PAST (return on equity)0 · sector 0
HEALTH (low debt)75 · sector 96
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $920.69 $1,275.02 +38% vs 383930
Vertex Pharmaceuticals Incorporated VRTX $515.02 $566.52 +10% vs 383930
Samsung Biologics Co 207940 ₩1,355,000 ₩1,490,500 +10% vs 383930
argenx SE ARGX $925.70 $908.40 −2% vs 383930
CSL Limited CSL A$197.29 A$188.80 −4% vs 383930
BeOne Medicines AG 6160 HK$230.80 HK$152.92 −34% vs 383930
Moderna, Inc MRNA $195.00 $122.98 −37% vs 383930
Revolution Medicines, Inc RVMD $161.20 $83.14 −48% vs 383930
Celltrion, Inc 068270 ₩213,000 ₩74,574 −65% vs 383930
Royalty Pharma plc RPRX $68.45 $19.01 −72% vs 383930

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

DT&CRO Co. Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "DT&CRO Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/383930

Frequently asked questions

Is DT&CRO Co. Ltd. (383930) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is ₩1,970 versus a price of ₩1,890, about +4% upside (fairly valued).
What is the fair value of 383930?
Our estimate for DT&CRO Co. Ltd. is ₩1,970 (as of Nov 16, 2026), built from audited fundamentals. The current price: ₩1,890.
What is the quality score of 383930?
DT&CRO Co. Ltd. has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DT&CRO Co. Ltd. (383930)?
We do not set a price target; the yardstick is our estimate of ₩1,970 (as of Nov 16, 2026). Cautious scenario ₩1,478, optimistic scenario ₩2,463. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the DT&CRO Co. Ltd. stock forecast for 2026?
Our estimate puts fair value at ₩1,970, about +4% upside versus a price of ₩1,890 (fairly valued). Cautious scenario ₩1,478, optimistic scenario ₩2,463. The calculation is refreshed regularly with new filings.
What is the revenue of DT&CRO Co. Ltd. (383930)?
DT&CRO Co. Ltd. reported trailing-twelve-month revenue of about 49.0B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of DT&CRO Co. Ltd. (383930)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DT&CRO Co. Ltd. it is ₩1,970 per share (as of Nov 16, 2026), against a price of ₩1,890.
Is DT&CRO Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 383930 trades below its calculated fair value: price ₩1,890, fair value ₩1,970, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 383930?
No. The price is what the market pays today (₩1,890); the fair value is what the company's own numbers justify (₩1,970). For DT&CRO Co. Ltd. the two are ₩80 per share apart. That gap is exactly why we show both numbers side by side.
How much is DT&CRO Co. Ltd. worth?
The market values DT&CRO Co. Ltd. at about 24.2B KRW (market capitalisation, as of Nov 16, 2026). Per share that is ₩1,890; our models calculate a fair value of ₩1,970 per share.
What do the bullish and bearish scenarios say about 383930?
Our models span a range for DT&CRO Co. Ltd.: cautious scenario ₩1,478, base ₩1,970, optimistic ₩2,463 per share (as of Nov 16, 2026, price ₩1,890). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DT&CRO Co. Ltd. (383930)?
Balance-sheet figures for DT&CRO Co. Ltd. (as of Nov 16, 2026): return on equity −105.1%, debt of 0.51 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is 383930 from its 52-week high?
DT&CRO Co. Ltd. trades at ₩1,890, about 50% below its 52-week high of ₩3,745 and 30% above the low of ₩1,450 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of ₩1,970 is for.
Which stocks are comparable to DT&CRO Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DT&CRO Co. Ltd. stock attractive at the current price?
The data as of Nov 16, 2026: price ₩1,890, calculated fair value ₩1,970 (+4%), Quality Score 33/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. DT&CRO Co. Ltd. currently trades 4% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DT&CRO Co. Ltd. (383930)?
The closing price on Nov 20, 2026 was ₩1,890. Our estimate is ₩1,970, about +4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DT&CRO Co. Ltd. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of DT&CRO Co. Ltd.

How large is the market capitalisation of DT&CRO Co. Ltd. (383930)?
The market capitalisation of DT&CRO Co. Ltd. is 24.2B KRW (≈ $18.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DT&CRO Co. Ltd. (383930)?
The price-to-sales ratio of DT&CRO Co. Ltd. is 0.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DT&CRO Co. Ltd. (383930)?
Earnings per share at DT&CRO Co. Ltd. are ₩-1,337. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of DT&CRO Co. Ltd. (383930)?
The net margin of DT&CRO Co. Ltd. is −34.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DT&CRO Co. Ltd. (383930)?
The return on equity (ROE) of DT&CRO Co. Ltd. is −105% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DT&CRO Co. Ltd. (383930)?
On an EBIT basis the return on assets of DT&CRO Co. Ltd. is −3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DT&CRO Co. Ltd. (383930)?
The operating margin of DT&CRO Co. Ltd. is −58.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DT&CRO Co. Ltd. (383930)?
Revenue at DT&CRO Co. Ltd. is growing 12.3% in the last quarter versus the same quarter a year earlier (3y avg +2.8%). How much revenue grew in the last quarter versus the same quarter a year earlier (YoY). The 3-year average next to it puts the single quarter in context.
How fast are earnings growing at DT&CRO Co. Ltd. (383930)?
Earnings per share at DT&CRO Co. Ltd. are down 93.6% in the last quarter versus the same quarter a year earlier. How much earnings per share grew in the last quarter versus the same quarter a year earlier.
How much free cash flow does DT&CRO Co. Ltd. (383930) generate?
The free cash flow of DT&CRO Co. Ltd. is −14.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does DT&CRO Co. Ltd. (383930) carry?
The net debt of DT&CRO Co. Ltd. is 33.9B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch DT&CRO Co. Ltd. in the live analysis

One click puts DT&CRO Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.